remedio tirzepatide (Mounjaro) In Sherman Oaks Most Successful Weight Loss Program. Compounded Tirzepatide
Description
Who is not eligible for Mounjaro
At week 26, LDL-C was reduced by 19.0% (-36.0% to -1.9%, p=.029) in the tirzepatide 15 mg group compared to placebo while it was reduced by 17.8% (-33.7% to -2.0%, p= 0.028) in the dulaglutide 1.5 mg group compared to placebo though differences between the 2 medications were not seen [60]
Patients taking orforglipron experienced an average weight loss of approximately 6.14 kg compared to those on placebo
However, not everyone will experience these side effects and some people tolerate one medication better than the other
